Clinical trials: Bronchiectasis
Non-Cystic Fibrosis Bronchiectasis
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
- Trial name
- ASPEN (NCT04594369)
- Testing
- Brensocatib 10 mg, Brensocatib 25 mg
- Where
- 373 sites in United States, Argentina and 34 more
- Volunteers
- 1,767 people
- Sponsor
- Insmed Incorporated
Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
A 2-part multi-center, Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of RHB-204 in adult subjects with underlying nodular bronchiectasis and documented MAC lung…
- Conditions
- Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases
- Trial name
- CleaR-MAC (NCT04616924)
- Testing
- RHB-204
- Where
- 25 sites in United States
- Volunteers
- 12 people
- Sponsor
- RedHill Biopharma Limited
Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life
This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.
- Trial name
- NCT05523180
- Testing
- Probiotic
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- ResBiotic Nutrition, Inc.
Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.
- Trial name
- NCT07696091
- Testing
- RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Bronchiectasis
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups.
- Trial name
- NCT06280391
- Testing
- Itepekimab (SAR440340)
- Where
- 117 sites in United States, Argentina and 18 more
- Volunteers
- 314 people
- Sponsor
- Sanofi
Bronchiectasis
Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population
The primary objective is to compare the patient's baseline QoL prior to HFCWO use against the patient's QoL at various study timepoints over a one-year period of HFCWO use.
- Trial name
- HFCWO (NCT04271969)
- Testing
- SmartVest Airway Clearance System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Electromed, Inc.
Bronchiectasis
Autologous Bronchial Basal Cells Transplantation for Treatment of Bronchiectasis
Bronchiectasis is a result of chronic inflammation compounded by an inability to clear mucoid secretions. Inflammation results in progressive destruction of the normal lung architecture, in particular the elastic fibers of…
- Trial name
- NCT02722642
- Testing
- Bronchial basal cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Regend Therapeutics
Non-cystic Fibrosis Bronchiectasis
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE.
- Trial name
- NCT05495243
- Testing
- ARINA-1
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Renovion, Inc.
Bronchiectasis
Safety and Efficacy of Bronchitol in Bronchiectasis
Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus).
- Trial name
- NCT00277537
- Testing
- Mannitol
- Where
- 22 sites in Australia, New Zealand and 1 more
- Volunteers
- 354 people
- Sponsor
- Syntara
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
Bronchiectasis Adult, COPD
Evaluation of the Effectiveness of The Volara System Determined by Sputum Movement and Production
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.
- Trial name
- NCT06937216
- Testing
- Volara therapy
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Baxter Healthcare Corporation
Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo
The rationale of this study is to conduct a summative (i.e., validation) usability test of Ciprofloxacin Dry Powder for Inhalation (DPI) and the associated Instructions for Use.
- Trial name
- NCT02661438
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bayer
Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
- Trial name
- NCT04010799
- Testing
- CHF 6333
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Bronchiectasis
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ).
- Trial name
- NCT05846230
- Testing
- BI 1291583
- Where
- 103 sites in United States, Australia and 20 more
- Volunteers
- 268 people
- Sponsor
- Boehringer Ingelheim
Non-cystic Fibrosis Bronchiectasis (NCFBE)
A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.
- Trial name
- NCT05601778
- Testing
- HSK31858
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non Cystic Fibrosis Bronchiectasis
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
The primary objective of the trial was to investigate the effect of the use of inhaled colistimethate sodium (CMS), administered twice a day (b.i.d.) via a specific nebulizer for 12 months, compared to placebo in subjects with…
- Trial name
- PROMIS-II (NCT03460704)
- Testing
- CMS
- Where
- 89 sites in United States, Argentina and 10 more
- Volunteers
- 287 people
- Sponsor
- Zambon SpA
Asthma, Bronchiectasis
A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.
- Trial name
- DAS181 (NCT01113034)
- Testing
- DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ansun Biopharma, Inc.
Bronchiectasis With Pseudomonas Aeruginosa Colonization
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
- Trial name
- CLEAR (NCT07088926)
- Testing
- AZD0292
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 435 people
- Sponsor
- AstraZeneca
Primary Ciliary Dyskinesia
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
- Trial name
- NCT05737485
- Testing
- RCT1100
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 9 people
- Sponsor
- ReCode Therapeutics
Chronic Respiratory Disease
Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF
Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE) or pulmonary fibrosis (PF) are usually not curable with damaged pulmonary structure and function.
- Trial name
- NCT03153800
- Testing
- bronchial basal cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Regend Therapeutics